• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Impel NeuroPharma Expands Commercial Team

    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Emergent BioSolutions

    Adare Pharma Solutions

    Flow Sciences

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Flow Sciences

    PCI Pharma Services

    Cytovance Biologics

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Parenteral Drug Trends

    Leading CDMOs discuss trends in the market for injectable drugs.

    Parenteral Drug Trends
    (Photo courtesy of LSNE)
    Tim Wright, Editor, Contract Pharma03.04.20
    Parenteral drugs are types of medications that require non-oral administration, mostly through the direct injection of drugs into the body of the patient either in intravenous, intramuscular, and subcutaneous methods.

    After oral administration, parenteral drug delivery is the most common way of getting drugs to patients. While more complex and costly to make than their oral counter-parts, parenteral drugs tout many advantages, such as greater bioavailability.

    The market for injectables has been growing steadily over the last decade and projected growth is strong and being driven by the increasing number of drugs approved each year and the booming biologics space.

    The emergence of orphan drug development to treat rare diseases is another area sparking growth, according to Marga Viñes, business development manager, contract manufacturing, Grifols International. “Recent successes in the development of orphan drugs coupled with productivity challenges in the classic pharma R&D model for indications with a higher prevalence have resulted in a number of major pharmaceutical companies establishing business units focused on rare diseases,” she said. “Investment by venture capital companies in early-stage biotechs with rare disease programs has also increased.”

    Increasing complexity of formulations and associated clinical trial process complications have limited the entry of new players within the parenteral field, according to Ms. Viñes. With increasing outsourcing activities, contract manufacturing companies are likely to gain advantage compared to in-house manufacturing facilities in the coming years.

    “The parenteral drug market continues to grow, but we’re seeing growth of the outsourced market surpassing the industry growth in general,” said Bert Barbosa, vice president, drug product, Ajinomoto Bio-Pharma Services. “There is an increasing number of emerging biopharmas that are developing products through late stage and thus requiring contract development and manufacturing organization (CDMO) support, as opposed to larger pharmas with internal manufacturing capabilities.”

    Jeff Clement, president of business development, LSNE Contract Manufacturing, said the market continues to move towards fully integrated CDMOs for not only the GMP manufacturing of their product, but for supporting formulation development, analytical development, and quality control services. “Vendor management is a critical concern for many companies seeking to reduce costs and manage their clinical or commercial supply efficiently,” he said.

    Growth drivers
    Personalized medicine looks to be a large part of the future of drug development and an area where CDMOs can invest heavily to support patient needs. “CDMO support will be needed to help development companies navigate the difficult regulatory, time and quality hurdles that currently raise concerns,” said Mr. Barbosa, “but the companies that are early adopters of innovative solutions between customers and regulatory authorities will be poised for taking advantage of this growing sector.

    Also, he said the number of oncology and potent drugs in development has dwarfed other therapeutic areas over the last decade, and that trend is likely to continue. “Within oncology there are HPAPI and ADC drugs that are poised for significant growth.”

    Today’s CDMO needs to stay abreast of trends in new formulations or drug delivery technologies. To that end, strong CDMOs will have technologies to support liposomal formulations, emulsions, suspensions, as well as new drug products being formulated with a variety of cyclodextrins, according to Mr. Clement.

    “Many companies have developed platform technologies, which are used for many products within the company’s pipeline,” he said. “LSNE has kept pace by developing programs which initiates a comprehensive lyophilization development program for the initial platform product and then performing an assessment of other APIs developed on our client’s platform technology. CDMOs working collaboratively with the developer on complex/aseptically processed projects are driving the business towards long term partnerships rather than one-off fills.”

    At the same time, some companies seem to be moving toward more complex administration systems. These novel pre-filled devices are more user-friendly for the patient and can help the company distinguish themselves from their competition, Mr. Clement said. “However, the early clinical stage production costs may be very high so many companies delay the decision to move towards these novel delivery systems until they have completed successful clinical trials with more traditional methods of administration. We anticipate that companies will continue to explore novel prefill devices but there will be challenges with filling them aseptically and lyophilizing them, if required.” 

    In recent years, Ms. Viñes reiterated that drug makers have shifted their focus from the development of blockbuster drugs to the development of therapies to treat rare diseases, also known as orphan drugs. “There have been 7000–8000 rare diseases identified to date—effective medicines have been developed for only a few hundred of these diseases,” she said.

    Concerning biologics, Ms. Viñes said that as a result of positive development and success in treatment of a majority of chronic diseases, “a large number of companies have been investing in research and development for these products.”

    The generics front offers other opportunities for growth. “Over the next 5 years, more than 30 drugs are likely to lose patent and go generic,” said Ms. Viñes. “With so many molecules converting to generics, there will be a lot of potential business for contract manufacturers focused on these types of drugs to capitalize on.”

    Market challenges
    By all accounts the market for the development and manufacture of injectable drugs is poised for tremendous growth. Despite the positive outlook, the CDMOs servicing the space face numerous challenges getting drugs to market.

    An increase in cost bases and the demand for investments to support larger and more diverse service offerings is posing a significant obstacle, according to Mr. Barbosa. “Clinical customers who need flexible support services require cost effective means of working with a CDMO partner to deal with clinical issues that arise,” he said. “CDMOs then must have manufacturing and quality systems that can adapt to the customer’s needs.”

    He continued, “Commercial customers face increasing pressure globally from regulators on costs of drugs and therefore need to partner with CDMOs to find mutually beneficial solutions to controlling costs and sharing savings over the life time of a drug. CDMO’s are in a tough position because they must try to accommodate the wide-ranging needs of clinical clients, but also have efficiencies in commercial manufacturing to cut costs down for partners and patients.”

    As regulatory requirements continue to tighten, Mr. Clement says he expects to see a greater emphasis on isolators and automated equipment which will reduce human intervention. “Our clients are focused on their timelines and speed to market so continuing to provide them with timely service will be paramount,” he said. “There will likely be a focus on innovation and both existing and new CMOs will need to have growth plans and options in place to move quickly with an expanded customer base or new technology. Also, with many more novel, complex projects coming to the market there will be a trend towards partnerships between CMOs and their clients.”

    Based on what he’s seen in the market over the last three years, Mr. Clement says he expects that the CMO industry will continue to grow, especially in the areas of fill/finish and lyophilization, to support parenteral drug product manufacturing. 

    As noted earlier, the manufacture of sterile parenteral products is generally more complex than the production of oral dosage forms. Patients, healthcare providers, suppliers and regulators have an implicit requirement of injectable drugs about their safety and effectiveness, according to Ms. Viñes.

    “A culture of quality and effective quality systems are essential for successful production of complex products such as sterile injectable,” she said. “It is imperative that all parenteral products be manufactured to the highest quality standards, regardless of whether they are branded drugs or generics. This demand includes the manufacture of injectable pharmaceuticals in compliance with uncompromising strict standards.” 
    Related Searches
    • Parenteral
    • generics
    • lyophilization
    • Dosage

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • Romaco Names Sales Directors in Cologne, Bologna and Karlsruhe
    • Impel NeuroPharma Expands Commercial Team
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Reports 2020 Annual Results
    AkzoNobel Completes Titan Paints Acquisition
    Mule-Hide Products Co. Promotes Steven Litaker to Territory Manager
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Modulation Technologies Acquires Contura Ltd.
    Solid Growth Forecast for Japan's MI Neurosurgical Devices Market
    Soundbite Medical Wins Health Canada Approval for PAD Treatment
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Romaco Names Sales Directors in Cologne, Bologna and Karlsruhe
    Impel NeuroPharma Expands Commercial Team
    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inter Parfums Reports a Strong Fourth Quarter
    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Happi

    Latest Breaking News From Happi

    Inter Parfums Bounces Back in Q4
    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    CP Printing adds Colordyne 3800 Series AP – Retrofit
    Edale names SMAG Graphique distributor in France
    TLMI analyzes pandemic's effect on label industry in new report
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Align Technology Inc. Executive Joins Zimmer Biomet Board
    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login